Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia

Thomas Briot,1,2 Emilie Roger,1 Nolwenn Lautram,1 Alexis Verger,1 Anne Clavreul,3,4 Frederic Lagarce1,2 1Micro & Nanomédecines Translationelles – MINT, UNIV Angers, INSERM 1066, CNRS 6021, Université Bretagne Loire, MINT IBS-CHU, 2Pharmacy Department, Univers...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Briot T, Roger E, Lautram N, Verger A, Clavreul A, Lagarce F
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	Lipid nanocapsules - Acute myeloid leukemia - Decitabine - Nanomedicine Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/10cc6ce309724deab6b1db65a8fc0bd4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:10cc6ce309724deab6b1db65a8fc0bd4
record_format	dspace
spelling	oai:doaj.org-article:10cc6ce309724deab6b1db65a8fc0bd42021-12-02T02:53:20ZDevelopment and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia1178-2013https://doaj.org/article/10cc6ce309724deab6b1db65a8fc0bd42017-11-01T00:00:00Zhttps://www.dovepress.com/development-and-in-vitro-evaluations-of-new-decitabine-nanocarriers-fo-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Thomas Briot,1,2 Emilie Roger,1 Nolwenn Lautram,1 Alexis Verger,1 Anne Clavreul,3,4 Frederic Lagarce1,2 1Micro & Nanomédecines Translationelles – MINT, UNIV Angers, INSERM 1066, CNRS 6021, Université Bretagne Loire, MINT IBS-CHU, 2Pharmacy Department, University Hospital of Angers, 3Neurosurgery Department, University Hospital of Angers, 4CRCINA, INSERM, Université de Nantes, Université d’Angers, Angers, France Abstract: Decitabine is a hydrophilic drug that acts by hypomethylating DNA. Decitabine is used in Europe for the treatment of acute myeloid leukemia (AML) in patients aged ≥65 years. However, it can only be administered intravenously due to very low oral bioavailability and a large distribution volume. Oral administration would allow outpatient treatment, improving quality of life and reducing treatment costs. The present study proposes to develop lipid nanocapsules (LNCs), originally designed for lipophilic drugs, to encapsulate decitabine. Two different formulations of LNCs were designed: LNCs based on a high proportion of Transcutol® HP (THP-LNCs) and LNCs associated with a mixture of Transcutol® HP and Tween® 80 (THP-T80-LNCs). The second formulation had a diameter of 26.5±0.5 nm, high encapsulation efficiency (>85%), and a drug payload of 472±64 µg/mL. Decitabine-loaded THP-T80-LNC cytotoxicity was evaluated on two AML cell lines depending on their decitabine resistance: HEL (not resistant) and HL-60 (resistant). The permeability of decitabine-loaded THP-T80-LNCs was also evaluated on Caco-2 cell monolayers. Decitabine cytotoxicity against HEL and HL-60 was higher when decitabine was loaded in THP-T80-LNCs than when free. Apparent permeability on Caco-2 cell monolayers was also increased, suggesting a potentially useful formulation to increase the oral bioavailability of decitabine. Keywords: lipid nanocapsules, acute myeloid leukemia, decitabine, nanomedicine, nanoparticles, oral administration, Caco2 cellsBriot TRoger ELautram NVerger AClavreul ALagarce FDove Medical PressarticleLipid nanocapsules - Acute myeloid leukemia - Decitabine - NanomedicineMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 12, Pp 8427-8442 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Lipid nanocapsules - Acute myeloid leukemia - Decitabine - Nanomedicine Medicine (General) R5-920
spellingShingle	Lipid nanocapsules - Acute myeloid leukemia - Decitabine - Nanomedicine Medicine (General) R5-920 Briot T Roger E Lautram N Verger A Clavreul A Lagarce F Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia
description	Thomas Briot,1,2 Emilie Roger,1 Nolwenn Lautram,1 Alexis Verger,1 Anne Clavreul,3,4 Frederic Lagarce1,2 1Micro & Nanomédecines Translationelles – MINT, UNIV Angers, INSERM 1066, CNRS 6021, Université Bretagne Loire, MINT IBS-CHU, 2Pharmacy Department, University Hospital of Angers, 3Neurosurgery Department, University Hospital of Angers, 4CRCINA, INSERM, Université de Nantes, Université d’Angers, Angers, France Abstract: Decitabine is a hydrophilic drug that acts by hypomethylating DNA. Decitabine is used in Europe for the treatment of acute myeloid leukemia (AML) in patients aged ≥65 years. However, it can only be administered intravenously due to very low oral bioavailability and a large distribution volume. Oral administration would allow outpatient treatment, improving quality of life and reducing treatment costs. The present study proposes to develop lipid nanocapsules (LNCs), originally designed for lipophilic drugs, to encapsulate decitabine. Two different formulations of LNCs were designed: LNCs based on a high proportion of Transcutol® HP (THP-LNCs) and LNCs associated with a mixture of Transcutol® HP and Tween® 80 (THP-T80-LNCs). The second formulation had a diameter of 26.5±0.5 nm, high encapsulation efficiency (>85%), and a drug payload of 472±64 µg/mL. Decitabine-loaded THP-T80-LNC cytotoxicity was evaluated on two AML cell lines depending on their decitabine resistance: HEL (not resistant) and HL-60 (resistant). The permeability of decitabine-loaded THP-T80-LNCs was also evaluated on Caco-2 cell monolayers. Decitabine cytotoxicity against HEL and HL-60 was higher when decitabine was loaded in THP-T80-LNCs than when free. Apparent permeability on Caco-2 cell monolayers was also increased, suggesting a potentially useful formulation to increase the oral bioavailability of decitabine. Keywords: lipid nanocapsules, acute myeloid leukemia, decitabine, nanomedicine, nanoparticles, oral administration, Caco2 cells
format	article
author	Briot T Roger E Lautram N Verger A Clavreul A Lagarce F
author_facet	Briot T Roger E Lautram N Verger A Clavreul A Lagarce F
author_sort	Briot T
title	Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia
title_short	Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia
title_full	Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia
title_fullStr	Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia
title_full_unstemmed	Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia
title_sort	development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/10cc6ce309724deab6b1db65a8fc0bd4
work_keys_str_mv	AT briott developmentandinvitroevaluationsofnewdecitabinenanocarriersforthetreatmentofacutemyeloidleukemia AT rogere developmentandinvitroevaluationsofnewdecitabinenanocarriersforthetreatmentofacutemyeloidleukemia AT lautramn developmentandinvitroevaluationsofnewdecitabinenanocarriersforthetreatmentofacutemyeloidleukemia AT vergera developmentandinvitroevaluationsofnewdecitabinenanocarriersforthetreatmentofacutemyeloidleukemia AT clavreula developmentandinvitroevaluationsofnewdecitabinenanocarriersforthetreatmentofacutemyeloidleukemia AT lagarcef developmentandinvitroevaluationsofnewdecitabinenanocarriersforthetreatmentofacutemyeloidleukemia
_version_	1718402023392542720

Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia

Ejemplares similares